BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

  Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide.

  February 8, 2024

   · 

  4 min read
• Deals

  Optimi Announces Non-Brokered Private Placement

  Optimi Health Corp. announces it intends to complete a non-brokered private placement of up to 5,000,000 units (each a “ Unit ”) at CAD$0.30 per Unit for gross proceeds of up to CAD$1,500,000 (the “ Offering ”).

  February 8, 2024

   · 

  4 min read
• Business

  Baxter Reports Fourth-Quarter and Full-Year 2023 Results

  Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

  February 8, 2024

   · 

  53 min read
• Business

  Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

  Collegium Pharmaceutical, Inc. today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024.

  February 8, 2024

   · 

  1 min read
• Genetown

  Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

  Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today announced the nomination of its first development candidate, AUTX-703.

  February 8, 2024

   · 

  3 min read
• Pharm Country

  Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

  Indaptus Therapeutics, Inc. is pleased to announce the launch of a new social media initiative to provide education and updates about the company.

  February 8, 2024

   · 

  7 min read
• Biotech Bay

  Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

  Neurona Therapeutics today announced the successful completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors.

  February 8, 2024

   · 

  8 min read
• Biotech Beach

  Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium

  Biora Therapeutics, Inc today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024.

  February 8, 2024

   · 

  3 min read
• Drug Development

  Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

  Madrigal Pharmaceuticals, Inc. today announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine.

  February 8, 2024

   · 

  12 min read
• Business

  Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

  PARIS, FRANCE, 8 February 2024 - Ipsen, a global specialty-care biopharmaceutical company, presents its financial results for the year and final quarter of 2023.

  February 8, 2024

   · 

  12 min read